• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 16, 2020

View Archived Issues
Silhouette of head, brain

Seven come eleven: Takeda makes Neurocrine wager in schizophrenia, depression, more

Neurocrine Biosciences Inc.’s chief business development and strategy officer, Kyle Gano, said “there was really no playbook” for the deal in which his firm is paying Takeda Pharmaceutical Co. Ltd. $120 million up front for an exclusive license to seven programs, including three clinical-stage assets targeting the notoriously difficult indications of schizophrenia and treatment-resistant depression (TRD), as well as depression-related anhedonia. Read More

Ideaya, GSK collaboration in synthetic lethality programs in oncology could be worth more than $3B

Glaxosmithkline plc (GSK) will collaborate in three of Ideaya Biosciences Inc.’s synthetic lethality programs, MAT2A (methionine adenosyltransferase 2a), Pol Theta (polymerase theta) and Werner Helicase, in a deal that Ideaya estimated could be worth billions. Read More
Gold dollar sign

C4 secures $170M to advance protein degrader pipeline

C4 Therapeutics Inc., a company focused on destroying disease-causing proteins via degradation, has closed a $170 million financing intended to help move four cancer candidates into the clinic by the end of 2022. Read More
covid-19-coronavirus-lungs

Dexamethasone shows benefit in treating COVID-19 in Recovery trial

LONDON – In the first major breakthrough in therapeutics for COVID-19 infection, dexamethasone has been shown to have a statistically significant impact on mortality in the most seriously ill patients. Read More
Argentinian flag

Argentina researchers pitting camelid-based antibody strategy against SARS-CoV-2

CAJICA, Colombia – A team of scientists in Argentina is working on obtaining monoclonal antibodies from hens and llamas in a bid to produce both a vaccine and a drug for SARS-CoV-2, but the development process is highlighting the challenges that researchers and scientists in developing countries with troubled economies can face. Read More
6-16 Yisheng-pic

Yisheng unveils PIKA adjuvanted recombinant protein vaccine candidate for COVID-19

BEIJING – One more company is joining the global efforts in developing a vaccine for COVID-19. Beijing-based Yisheng Biopharma Co. Ltd. unveiled YS-SC2-010, which was developed through recombinant protein technology and its proprietary PIKA (polyinosinic-polycytidylic acid-based adjuvant) technology. Read More

Etherna closes $38M series B round for mRNA vaccine push in COVID-19, cancer

DUBLIN – Etherna Immunotherapies NV raised €34 million (US$38.2 million) in a series B funding round to progress its pipeline of mRNA-based vaccines for cancer and infectious disease. Read More

Ona takes on cancer metastases, raises $34M in series A

LONDON - Ona Therapeutics SL has raised €30 million (US$33.9 million) in a series A round, providing the means to advance a new method of treating metastases by blocking the lipid metabolism of cancer cells. Read More

Seikagaku, Ono Pharma plan next steps for arthritis drug after positive Japan phase III results

HONG KONG – Japan’s Seikagaku Corp. is contemplating the next move for its ONO-5704/SI-613 (diclofenac etalhyaluronate), a treatment for arthritis that it is co-developing with fellow Japanese company Ono Pharmaceutical Co. Ltd. Read More
Insight-Golden-Ticket-pic-6-16

Drug developers' Golden Ticket

It won't get you the right to see the Oompa Loompas, but a Golden Ticket for MBC Biolabs could be even more valuable to a startup. Read More
Beta cells

Diogenx launches new search for holy grail of diabetes

Beta cell regeneration has been a holy grail for type 1 diabetes researchers for several decades. Despite some promising results in animal models, progress in patients has remained frustratingly elusive, however. Read More

Appointments and advancements for June 16, 2020

New hires and promotions in the biopharma industry, including: Adverum, Biovie, Bioxcel, Canbridge, Cure, Macrogenics, Novavax, Nurix, Zealand. Read More

Financings for June 16, 2020

Biopharmas raising money in public or private financings, including: 4D Molecular, Aveo Oncology, Cardiff Oncology, Celldex, Chemocentryx, Corat, Greenlight Biosciences, Medincell, Noxxon, Oncolytics, Portage Biotech, Therapeutics Acquisition, Royalty Pharma, Yumab. Read More

In the clinic for June 16, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Addex, Amarin, Anavex, Arecor, Bionic Sight, Dermavant, Enb, Exicure, Forma, Humanigen, Immunicum, Janssen, Merck, Neuren, Oncopeptides, PDS, Pfizer, Provention, Renibus, Sanofi, Sarepta, Vyome. Read More

Other news to note for June 16, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adamis, Agex, Aldevron, Amyndas, Annovis, Astrazeneca, Cascade, Cobra, Forte, Genprex, Hoth, Ichor, Immunomic, Kalytera, Lead Discovery Center, Matrix, QLi5, Qurient, Moleculin, Monopar, Northstar, Olix, Peptc Vaccines, PJSC Pharmsynthez, Pluristyx, Quartesian, Renibus, Salzman, Sanofi, Tocagen, Treos, Vyripharm, Xenetic. Read More

Regulatory actions for June 16, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akili, Arch, Edesa, Eli Lilly, Jazz, Valeo. Read More

Regulatory front for June 16, 2020

The latest global regulatory news, changes and updates affecting biopharma, including: Amgen, Esperion, Gilead, Lilly, Merck, Novartis. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe